International Stem Cell (ISCO) Research & Development (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Research & Development of $611000.0 for Q4 2025, up 112.15% year-over-year from $288000.0 in Q4 2024, and up 118.21% quarter-over-quarter from $280000.0 in Q3 2025.
International Stem Cell (ISCO) Research & Development (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Research & Development for 16 consecutive years, with $611000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development rose 112.15% year-over-year to $611000.0; the TTM figure through Dec 2025 stood at $1.2 million (up 39.01% YoY), while the FY2025 annual figure was $1.1 million, down 8.06% from the prior year.
- Research & Development advanced to $611000.0 in Q4 2025 per ISCO's latest filing, from $280000.0 in the prior quarter.
- Across five years, Research & Development topped out at $611000.0 in Q4 2025 and bottomed at $83000.0 in Q2 2022.
- Historically, Research & Development has averaged $238950.0 across 5 years, with a median of $201000.0 in 2021.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 76.22% — and 2023, when it soared 272.29%.
- International Stem Cell's Research & Development stood at $334000.0 in 2021, then slumped by 62.57% to $125000.0 in 2022, then jumped by 32.8% to $166000.0 in 2023, then surged by 73.49% to $288000.0 in 2024, then surged by 112.15% to $611000.0 in 2025.
- Business Quant data shows ISCO's Research & Development at $611000.0 in Q4 2025, $280000.0 in Q3 2025, and $162000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 276,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 276,000.00 |
| Dec 31, 2025 | 611,000.00 |
| Sep 30, 2025 | 280,000.00 |
| Jun 30, 2025 | 162,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Dec 31, 2024 | 288,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 334,000.00 |
| Dec 31, 2023 | 166,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 309,000.00 |
| Mar 31, 2023 | 315,000.00 |
| Dec 31, 2022 | 125,000.00 |
| Sep 30, 2022 | 147,000.00 |
| Jun 30, 2022 | 83,000.00 |
| Mar 31, 2022 | 137,000.00 |
| Dec 31, 2021 | 334,000.00 |
| Sep 30, 2021 | 165,000.00 |
| Jun 30, 2021 | 349,000.00 |